Alkermes plc (ALKS)

Market Cap	5.40B
Revenue (ttm)	1.56B
Net Income (ttm)	367.07M
Shares Out	162.61M
EPS (ttm)	2.17
PE Ratio	15.30
Forward PE	18.07
Dividend	n/a
Ex-Dividend Date	n/a

Volume	922,403
Open	33.66
Previous Close	33.53
Day's Range	33.08 - 33.72
52-Week Range	22.90 - 36.45
Beta	0.58
Analysts	Buy
Price Target	39.50 (+18.94%)
Earnings Date	Apr 30, 2025

About ALKS

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable su...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jul 16, 1991
• Employees: 1,800
• Stock Exchange: NASDAQ
• Ticker Symbol: ALKS
• Website: https://www.alkermes.com

Financial Performance

In 2024, Alkermes's revenue was $1.56 billion, a decrease of -6.36% compared to the previous year's $1.66 billion. Earnings were $367.07 million, an increase of 3.18%.

Analyst Forecast

According to 13 analysts, the average rating for ALKS stock is "Buy." The 12-month stock price forecast is $39.5, which is an increase of 18.94% from the latest price.

Price Target

$39.5

(18.94% upside)

Analyst Consensus: Buy